Compare DGICA & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DGICA | CBIO |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | United States | United States |
| Employees | 851 | 44 |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.0M | 557.8M |
| IPO Year | N/A | N/A |
| Metric | DGICA | CBIO |
|---|---|---|
| Price | $17.20 | $18.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $19.00 | ★ $26.67 |
| AVG Volume (30 Days) | 107.3K | ★ 222.5K |
| Earning Date | 04-30-2026 | 05-23-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.43 | $8.72 |
| 52 Week High | $21.06 | $20.58 |
| Indicator | DGICA | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 63.23 |
| Support Level | $16.52 | $10.89 |
| Resistance Level | $17.48 | $20.58 |
| Average True Range (ATR) | 0.30 | 1.77 |
| MACD | 0.08 | 0.20 |
| Stochastic Oscillator | 50.58 | 71.13 |
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.